SPOTLIGHT: Elbion in pact with Wyeth

Belgium's Elbion will collaborate with Wyeth on a new schizophrenia drug. Elbion stands to gain up to $110 million in the deal. Elbion's research has focused on inhibiting PDE 10 to improve the function of neurons. Wyeth also struck a deal with Nautilus to develop a new therapy for hemophilia B, though no financial details were provided for that pact. Release on Elbion; Release on Nautilus

Suggested Articles

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.